鉴定了一种p21激活激酶1 (PAK1) 抑制剂,对PAK2具有10倍的选择性
Deidre M Johns1, Jason Olejniczak1, Anjali Babbar1
1Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company), 10628 Science Center Drive, Suite 200, San Diego, CA 92121, United States.
Bioorganic & medicinal chemistry letters
|June 14, 2025
概括
研究人员开发了一种新的小分子抑制剂,向p21激活激酶1 (PAK1),对癌症至关重要. 这种抑制剂对PAK1比PAK2具有十倍的选择性,这是一种与心脏毒性相关的相关蛋白质.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 通过p21激活酶 (PAKs) 调节细胞骨,细胞形状和生存.
- PAK1与瘤发生有关,并在乳腺癌,卵巢癌和黑色素瘤癌症中被放大.
- 尽管结构上与PAK1相似,但PAK2与心脏毒性有关.
研究的目的:
- 设计一种小分子抑制剂,对PAK1具有选择性,而不是PAK2.
- 利用结构信息,针对针对PAK的药物开发1.1.
主要方法:
- 确定了PAK2.2的第一个晶体结构.
- 采用基于结构的药物设计原则.
- 合成并测试了小分子抑制剂的PAK1/PAK2选择性.
主要成果:
- 报告了PAK2.2的第一个晶体结构.
- 设计并确定了一种新的小分子抑制剂.
- 实现了PAK1抑制的十倍选择性,而不是PAK2.
结论:
- 第一个PAK2晶体结构允许基于结构的PAK1选择性抑制剂的设计.
- 这种选择性抑制剂代表了对PAK1驱动癌症的有前途的治疗策略.
- 准PAK1,同时省略PAK2可能会减轻心脏毒性问题.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


